The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of genomic alterations in circulating tumor DNA (ctDNA) with clinical response to telisotuzumab vedotin (Teliso-V) in 2L+ EGFR wildtype (EGFRwt) non-squamous non-small cell lung cancer (NSCLC) patients (pts) with c-Met overexpression (OE).
 
David Camidge
Honoraria - Abbvie; Apollomics; AstraZeneca; Daiichi Sankyo; Janssen; Kestrel Labs; Lilly; Nuvalent, Inc.; Roche; takeda
Research Funding - Inivata (Inst)
 
Shun Lu
Leadership - Innovent BIOLOGICS, INC; Shanghai Fosun; Simcere Zaiming
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)
 
Jonathan Goldman
Consulting or Advisory Role - AbbVie; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech; Summit Biomedical
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Pfizer (Inst); Summit Biomedical (Inst)
 
Hidehito Horinouchi
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; BlossomHill Therapeutics, Inc.; Chugai Pharma; Daiichi Sankyo; Genmab; Novocure; Seagen; Yuhan
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BlossomHill Therapeutics, Inc. (Inst); BMKK (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genmab (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Christine Ratajczak
Employment - Abbvie
Stock and Other Ownership Interests - AbbVie
 
Shilpen Patel
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Xizhi (Adam) Luo
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Yan Sun
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Shanmugapriya Ganesan
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Hossein Foroushani
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Yilin Xu
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Qu Zhang
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Tony Navas
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Peter Ansell
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Jair Bar
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Janssen Oncology; Medison; Merck Serono; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Immunai (Inst); MSD (Inst); Novartis (Inst); Oncohost (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)